learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 773 results
research Increased Lactate Dehydrogenase Activity Is Dispensable in Squamous Carcinoma Cells of Origin
High lactate dehydrogenase activity is not necessary for the growth of squamous cell carcinoma.
research Defining Metabolic Flexibility in Hair Follicle Stem Cell Induced Squamous Cell Carcinoma
Blocking both main energy pathways can stop hair follicle stem cell-induced skin cancer growth.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research High Fat Diet and the Adipocyte to Myofibroblast Transition: Implications for Systemic Sclerosis Cutaneous Fibrosis
A high fat lard diet may protect against skin fibrosis and affect hair growth.
research Next Generation Human Skin Constructs as Advanced Tools for Drug Development
Advanced human skin models improve drug development and could replace animal testing.
Community Join
5 / 107 resultscommunity Pelage Pharmaceuticals' PP405 listed on Time Magazine's List of Best Inventions of 2025
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community New Study: PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and stimulate natural hair growth by 20%
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.